February 2019
Acquired RNA-loaded dendritic cell platform technology and assets of Argos Therapeutics
coIMMUNE® incorporated in Delaware
April 2020
Acquired CAR-CIK platform technology through acquisition of Formula Pharmaceuticals
July 2020
Initiated Phase 2b coIMMUNE-sponsored RNA-loaded DC trial for RCC (CMN-001)
October 2020
Completed $45M Series A financing
December 2020
Completed investigator-initiated Phase 1/2a CAR-CIK trial for ALL (CMN-005)
October 2021
Partnership with cancer center for CAR-CIK in solid tumors
September 2022
Started investigator-initiated repeat dosing trial with CMN-005 in ALL
